Acquired Haemophilia A and COVID‐19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database
Haemophilia · 2026
DOI: 10.1111/hae.70303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Marine Laeng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regional Pharmacovigilance Center of Marseille, CHU de Marseille - Hôpital Sainte Marguerite, INSERM UMR 1106 Institut de Neurosciences des Systèmes,…. Hauptthemen laut MEDLINE: Hemophilia A, BNT162 Vaccine, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Acquired haemophilia A (AHA) is a rare autoimmune bleeding disorder commonly associated with autoimmune disorders, malignancies, infections, pregnancy, and certain medications. During the COVID‐19 vaccination campaign, several case reports have documented instances of AHA occurring subsequent to SARS‐CoV‐2 vaccination. In France, enhanced real‐time surveillance for adverse drug reactions (ADRs) associated with tozinameran/BNT162b2 (Pfizer‐BioNTech, Comirnaty) identified a potential signal for AHA in April 2021.
Objectives
To investigate the potential signal for AHA following tozinameran vaccination by analyzing spontaneous reports recorded in the French Pharmacovigilance Database (FPVD). Patients/Methods We conducted pharmacological and medical analyses of AHA cases following tozinameran vaccination registered in the FPVD. A total of 27 cases were included.
Results
AHA typically occurred after the second dose with a median onset of 23 days. The most frequent symptom was spontaneous haematoma. Haemorrhagic syndrome was severe in 19 cases due to associated anaemia. Seventeen patients received anti‐haemorrhagic agents, and 23 patients were treated with corticosteroids alone or combined with immunosuppressive agents. The mortality rate was 15%. No alternative etiology for AHA was identified in most cases, despite thorough investigations. Two patients experienced worsening of symptoms after re‐exposure to tozinameran.
Conclusions
This study supports a potential AHA signal with tozinameran, emphasizing the need for awareness among healthcare professionals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Pharmacovigilance Center of Marseille, CHU de Marseille - Hôpital Sainte Marguerite, INSERM UMR 1106 Institut de Neurosciences des Systèmes, Marseille, France.
- Regional Pharmacovigilance Center of Strasbourg, CHU de Strasbourg - Hôpital Civil, Strasbourg, France.
- Regional Pharmacovigilance Center of Lille, CHRU de Lille, Lille, France.
- Regional Pharmacovigilance Center of Angers, CHRU de Angers, Angers, France.
- Internal Medicine Department, Resource and Competence Center for Congenital Bleeding Disorders, CHU de Toulouse, Toulouse, France.
Zitieren
APA
Laeng, M., Lambert, A., Gautier, S., Briet, M., Piel-Julian, M. L., & Micallef, J. (2026). Acquired Haemophilia A and COVID‐19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database. Haemophilia. https://doi.org/10.1111/hae.70303
Vancouver
Laeng M, Lambert A, Gautier S, Briet M, Piel-Julian ML, Micallef J. Acquired Haemophilia A and COVID‐19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database. Haemophilia. 2026. doi:10.1111/hae.70303
BibTeX
@article{Laeng2026,
author = {Laeng, Marine and Lambert, Aude and Gautier, Sophie and Briet, Marie and Piel-Julian, Marie-Léa and Micallef, Joëlle},
title = {Acquired Haemophilia A and COVID‐19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70303}
}
EUVIMED